472 related articles for article (PubMed ID: 16373959)
1. Pharmaceutical expenditure compared across countries.
van Mosseveld C
Can J Clin Pharmacol; 2005; 12(3):e269-75. PubMed ID: 16373959
[TBL] [Abstract][Full Text] [Related]
2. Drugs still influence health costs, but trend abating.
Capitation Rates Data; 2003 Oct; 8(10):114-20. PubMed ID: 14621548
[No Abstract] [Full Text] [Related]
3. Pharmaceutical expenditure, total health-care expenditure and GDP.
Clemente J; Marcuello C; Montañés A
Health Econ; 2008 Oct; 17(10):1187-206. PubMed ID: 18050150
[TBL] [Abstract][Full Text] [Related]
4. How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countries.
Kemp A; Preen DB; Glover J; Semmens J; Roughead EE
Aust Health Rev; 2011 Aug; 35(3):341-9. PubMed ID: 21871197
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical expenditure and therapeutic value of new medicines in Spain.
Darba J
Pharmacoeconomics; 2003; 21(16):1211-2. PubMed ID: 14594440
[No Abstract] [Full Text] [Related]
6. The cost and availability of prescription drugs--what can we do in Massachusetts?
Carpenter NW; Kedikoglou S
Issue Brief (Mass Health Policy Forum); 1999 May; (4):1-41. PubMed ID: 12769091
[No Abstract] [Full Text] [Related]
7. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
Martikainen J; Kivi I; Linnosmaa I
Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
[TBL] [Abstract][Full Text] [Related]
8. [Proposal on reviewing the overall healthcare expenditure and its allocation: focusing on medication expenses].
Takamuku M
Nihon Geka Gakkai Zasshi; 2010 May; 111(3):189-94. PubMed ID: 20540336
[No Abstract] [Full Text] [Related]
9. Drug costs can be defended.
Lee AM
Med Mark Media; 1982 Mar; 17(3):36, 38, 40 passim. PubMed ID: 10309584
[No Abstract] [Full Text] [Related]
10. Fake pharmaceuticals: how they and relevant legislation or lack thereof contribute to consistently high and increasing drug prices.
Moken MC
Am J Law Med; 2003; 29(4):525-42. PubMed ID: 15119247
[No Abstract] [Full Text] [Related]
11. Prescription drug pricing: the consumer perspective.
Searing A
N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
[No Abstract] [Full Text] [Related]
12. Economic and policy implications of reimportation: a Canadian perspective.
Ward C
Manag Care; 2004 Mar; 13(3 Suppl):17-20. PubMed ID: 15074165
[No Abstract] [Full Text] [Related]
13. Prescription drugs: the facts about Canada.
Consum Rep; 2005 Oct; 70(10):50-1. PubMed ID: 16163821
[No Abstract] [Full Text] [Related]
14. The European value-pricing game.
McGuire A
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):5-6. PubMed ID: 22280188
[No Abstract] [Full Text] [Related]
15. Pharmaceutical pricing and reimbursement reforms in Greece.
Yfantopoulos J
Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
[TBL] [Abstract][Full Text] [Related]
16. Seizures of Canadian drugs rise as Congress, Customs spar.
Carreyrou J
Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16909501
[No Abstract] [Full Text] [Related]
17. How New Zealand has contained expenditure on drugs.
Cumming J; Mays N; Daubé J
BMJ; 2010 May; 340():c2441. PubMed ID: 20483927
[No Abstract] [Full Text] [Related]
18. The pricing of pharmaceuticals: an international comparison.
Dickson M
Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
[TBL] [Abstract][Full Text] [Related]
19. Medicare should bargain for lower drug prices, study says.
Med Health; 2005 Oct; 59(36):1, 3, 7. PubMed ID: 16240494
[No Abstract] [Full Text] [Related]
20. Pharmaceutical costs. An overview and analysis of legal and policy responses by the states.
Latham SR
J Leg Med; 2003 Jun; 24(2):141-73. PubMed ID: 12775406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
